Logo image of IONS

IONIS PHARMACEUTICALS INC (IONS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IONS - US4622221004 - Common Stock

79.93 USD
-0.72 (-0.89%)
Last: 12/26/2025, 8:00:02 PM
79.93 USD
0 (0%)
After Hours: 12/26/2025, 8:00:02 PM
Fundamental Rating

3

IONS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. Both the profitability and financial health of IONS have multiple concerns. IONS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year IONS has reported negative net income.
In the past year IONS has reported a negative cash flow from operations.
In the past 5 years IONS always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: IONS reported negative operating cash flow in multiple years.
IONS Yearly Net Income VS EBIT VS OCF VS FCFIONS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

1.2 Ratios

IONS has a Return On Assets of -8.45%. This is amongst the best in the industry. IONS outperforms 84.34% of its industry peers.
Looking at the Return On Equity, with a value of -41.48%, IONS is in the better half of the industry, outperforming 70.19% of the companies in the same industry.
Industry RankSector Rank
ROA -8.45%
ROE -41.48%
ROIC N/A
ROA(3y)-12.67%
ROA(5y)-11.54%
ROE(3y)-72.98%
ROE(5y)-56.49%
ROIC(3y)N/A
ROIC(5y)N/A
IONS Yearly ROA, ROE, ROICIONS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

Looking at the Gross Margin, with a value of 98.78%, IONS belongs to the top of the industry, outperforming 98.11% of the companies in the same industry.
In the last couple of years the Gross Margin of IONS has remained more or less at the same level.
IONS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.08%
GM growth 5Y-0.24%
IONS Yearly Profit, Operating, Gross MarginsIONS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

3

2. Health

2.1 Basic Checks

IONS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IONS has more shares outstanding
IONS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, IONS has an improved debt to assets ratio.
IONS Yearly Shares OutstandingIONS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
IONS Yearly Total Debt VS Total AssetsIONS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 2.79 indicates that IONS is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.79, IONS is in the better half of the industry, outperforming 67.92% of the companies in the same industry.
A Debt/Equity ratio of 0.96 indicates that IONS is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.96, IONS is doing worse than 76.79% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.96
Debt/FCF N/A
Altman-Z 2.79
ROIC/WACCN/A
WACC8.16%
IONS Yearly LT Debt VS Equity VS FCFIONS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

A Current Ratio of 2.79 indicates that IONS has no problem at all paying its short term obligations.
With a Current ratio value of 2.79, IONS is not doing good in the industry: 67.55% of the companies in the same industry are doing better.
A Quick Ratio of 2.78 indicates that IONS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.78, IONS is doing worse than 65.66% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.79
Quick Ratio 2.78
IONS Yearly Current Assets VS Current LiabilitesIONS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

5

3. Growth

3.1 Past

IONS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.74%, which is quite impressive.
Looking at the last year, IONS shows a very strong growth in Revenue. The Revenue has grown by 20.41%.
The Revenue has been decreasing by -8.88% on average over the past years.
EPS 1Y (TTM)30.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.79%
Revenue 1Y (TTM)20.41%
Revenue growth 3Y-4.54%
Revenue growth 5Y-8.88%
Sales Q2Q%17.16%

3.2 Future

Based on estimates for the next years, IONS will show a very strong growth in Earnings Per Share. The EPS will grow by 27.49% on average per year.
Based on estimates for the next years, IONS will show a very strong growth in Revenue. The Revenue will grow by 31.64% on average per year.
EPS Next Y23.99%
EPS Next 2Y-0.28%
EPS Next 3Y15.8%
EPS Next 5Y27.49%
Revenue Next Year44.89%
Revenue Next 2Y21.5%
Revenue Next 3Y30.11%
Revenue Next 5Y31.64%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IONS Yearly Revenue VS EstimatesIONS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B
IONS Yearly EPS VS EstimatesIONS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IONS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IONS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IONS Price Earnings VS Forward Price EarningsIONS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IONS Per share dataIONS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as IONS's earnings are expected to grow with 15.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.28%
EPS Next 3Y15.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IONS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

IONIS PHARMACEUTICALS INC

NASDAQ:IONS (12/26/2025, 8:00:02 PM)

After market: 79.93 0 (0%)

79.93

-0.72 (-0.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29 2025-10-29/bmo
Earnings (Next)02-17 2026-02-17/amc
Inst Owners106.64%
Inst Owner Change20.06%
Ins Owners0.72%
Ins Owner Change-6.28%
Market Cap12.95B
Revenue(TTM)966.96M
Net Income(TTM)-256.34M
Analysts82.67
Price Target87.25 (9.16%)
Short Float %9.72%
Short Ratio6.24
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)147.99%
Min EPS beat(2)36.42%
Max EPS beat(2)259.57%
EPS beat(4)4
Avg EPS beat(4)89.18%
Min EPS beat(4)18.36%
Max EPS beat(4)259.57%
EPS beat(8)8
Avg EPS beat(8)66.23%
EPS beat(12)11
Avg EPS beat(12)44.13%
EPS beat(16)14
Avg EPS beat(16)62.35%
Revenue beat(2)2
Avg Revenue beat(2)33.86%
Min Revenue beat(2)17.57%
Max Revenue beat(2)50.14%
Revenue beat(4)4
Avg Revenue beat(4)33.17%
Min Revenue beat(4)3.26%
Max Revenue beat(4)61.73%
Revenue beat(8)7
Avg Revenue beat(8)31.12%
Revenue beat(12)10
Avg Revenue beat(12)23.51%
Revenue beat(16)13
Avg Revenue beat(16)22.62%
PT rev (1m)10.72%
PT rev (3m)19.14%
EPS NQ rev (1m)-0.52%
EPS NQ rev (3m)-0.92%
EPS NY rev (1m)2.04%
EPS NY rev (3m)10.08%
Revenue NQ rev (1m)0.75%
Revenue NQ rev (3m)6.74%
Revenue NY rev (1m)1.33%
Revenue NY rev (3m)4.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.39
P/FCF N/A
P/OCF N/A
P/B 20.95
P/tB 20.95
EV/EBITDA N/A
EPS(TTM)-1.69
EYN/A
EPS(NY)-3.06
Fwd EYN/A
FCF(TTM)-1.87
FCFYN/A
OCF(TTM)-1.53
OCFYN/A
SpS5.97
BVpS3.82
TBVpS3.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.45%
ROE -41.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.78%
FCFM N/A
ROA(3y)-12.67%
ROA(5y)-11.54%
ROE(3y)-72.98%
ROE(5y)-56.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.08%
GM growth 5Y-0.24%
F-Score5
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.96
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1473.37%
Cap/Sales 5.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.79
Quick Ratio 2.78
Altman-Z 2.79
F-Score5
WACC8.16%
ROIC/WACCN/A
Cap/Depr(3y)219.39%
Cap/Depr(5y)190.33%
Cap/Sales(3y)4.04%
Cap/Sales(5y)3.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.79%
EPS Next Y23.99%
EPS Next 2Y-0.28%
EPS Next 3Y15.8%
EPS Next 5Y27.49%
Revenue 1Y (TTM)20.41%
Revenue growth 3Y-4.54%
Revenue growth 5Y-8.88%
Sales Q2Q%17.16%
Revenue Next Year44.89%
Revenue Next 2Y21.5%
Revenue Next 3Y30.11%
Revenue Next 5Y31.64%
EBIT growth 1Y24.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.76%
EBIT Next 3Y22.81%
EBIT Next 5YN/A
FCF growth 1Y46.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.31%
OCF growth 3YN/A
OCF growth 5YN/A

IONIS PHARMACEUTICALS INC / IONS FAQ

What is the fundamental rating for IONS stock?

ChartMill assigns a fundamental rating of 3 / 10 to IONS.


What is the valuation status for IONS stock?

ChartMill assigns a valuation rating of 0 / 10 to IONIS PHARMACEUTICALS INC (IONS). This can be considered as Overvalued.


What is the profitability of IONS stock?

IONIS PHARMACEUTICALS INC (IONS) has a profitability rating of 3 / 10.


How financially healthy is IONIS PHARMACEUTICALS INC?

The financial health rating of IONIS PHARMACEUTICALS INC (IONS) is 3 / 10.